Synthetic PET From CT Improves Precision Diagnosis and Treatment of Lung Cancer: a Prospective, Observational, Multicenter Study

NCT ID: NCT07243873

Last Updated: 2025-11-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

10000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-12-01

Study Completion Date

2026-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to synthesise PET data that preserves biological relevance and adds clinical value to the diagnosis and prognosis of lung cancer by establishing anatomical-to-metabolic mapping based on paired diagnostic CT and FDG-PET scans, thereby prospectively validating the clinical utility of the model.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer PET-CT

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PET-CT

A PET-CT scan is performed prior to initiating systemic treatment for the tumour.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with non-small cell lung cancer scheduled to undergo PET-CT and pathological examinations;
2. Voluntarily participate and sign an informed consent form;

Exclusion Criteria

1. History of other malignant tumours;
2. Image artefacts;
3. Without pathological diagnostic information;
4. Without paired CT and FDG-PET scan images.
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shanghai Pulmonary Hospital, Shanghai, China

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Chang Chen

Chief Physician

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Affiliated Hospital of Zunyi Medical University

Zunyi, Guizhou, China

Site Status RECRUITING

The First Affiliated Hospital of Nanchang University

Jiangxi, Nanchang, China

Site Status RECRUITING

Shanghai East Hospital

Shanghai, Shanghai Municipality, China

Site Status RECRUITING

Shanghai Pulmonary Hospital

Shanghai, Shanghai Municipality, China

Site Status RECRUITING

Ningbo No.2 Hospital

Ningbo, Zhejiang, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Xinchen Shen

Role: CONTACT

17366690957

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Yongxiang Song, Dr

Role: primary

0851 2862 3430

Bentong Yu, Dr

Role: primary

0791 8869 2765

Haiyan Wang

Role: primary

021-38804518

Xinchen Shen

Role: primary

17366690957

Minglei Yang, Dr

Role: primary

0574-88120120

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PETgeneration

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

⁶⁸Ga-DPA in the Lung Cancer Diagnosis
NCT07023068 ENROLLING_BY_INVITATION EARLY_PHASE1